# Phase I/II Study of Avelumab in Pediatric Cancer Participants

> **NCT03451825** · PHASE1 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Refractory or Relapsed Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03451825
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-07
- **Primary completion:** 2021-07-27
- **Final completion:** 2021-07-27
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Based on the limited activity observed with avelumab monotherapy in the pediatric population, the Phase II study part was cancelled.
- **Last updated:** 2024-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03451825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03451825, "Phase I/II Study of Avelumab in Pediatric Cancer Participants". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03451825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*